Medicare Enrolled
Dr. Maria Aloba, M.D.
Medical Oncology · El Paso, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Aloba from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Aloba? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Aloba
Dr. Maria Aloba is a medical oncology in El Paso, TX, with 19 years in practice. Based on federal Medicare data, Dr. Aloba performed 26,477 Medicare services across 3,475 unique beneficiaries.
Between the years covered by Open Payments, Dr. Aloba received a total of $71,149 from 42 pharmaceutical and/or device companies across 126 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Aloba is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 33% volume in TX$ $71,149 industry payments
Medicare Practice Summary
Medicare Utilization ↗26,477
Medicare services
Top 33% in TX for medical oncology
3,475
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,394 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) | 9,600 | $0 | $5 |
| Contrast dye for imaging (iodine-based) | 3,393 | $0 | $3 |
| Dexamethasone injection (steroid) | 1,866 | $0 | $1 |
| Blood draw (venipuncture) | 1,673 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,515 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,332 | $10 | $64 |
| Lactate dehydrogenase (enzyme) level | 861 | $6 | $31 |
| Anti-nausea injection (Aloxi/palonosetron) | 730 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 630 | $0 | $24 |
| Office visit, established patient (30-39 min) | 517 | $94 | $368 |
| Injection, fluorouracil, 500 mg | 460 | $2 | $13 |
| Injection of additional new drug or substance into vein | 406 | $11 | $108 |
| Hospital follow-up visit, moderate complexity | 300 | $61 | $247 |
| Administration of chemotherapy into vein, 1 hour or less | 225 | $94 | $707 |
| Reticulated (young) platelet measurement | 217 | $35 | $143 |
| Office visit, established patient (20-29 min) | 177 | $63 | $250 |
| Injection, zoledronic acid, 1 mg | 137 | $7 | $431 |
| Ferritin level test (iron stores) | 130 | $13 | $60 |
| Iron level test | 130 | $6 | $27 |
| Iron binding capacity test | 130 | $9 | $35 |
| Drug injection, under skin or into muscle | 119 | $10 | $96 |
| Magnesium level test | 104 | $6 | $29 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 103 | $91 | $657 |
| Vitamin B-12 level test | 99 | $15 | $76 |
| Folic acid level test | 99 | $14 | $73 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 93 | $1,105 | $4,802 |
| Microscopic examination for white blood cells with manual cell count | 89 | $4 | $22 |
| Complete blood count (CBC), automated | 89 | $6 | $34 |
| Initial hospital admission, moderate complexity | 89 | $98 | $470 |
| Administration of chemotherapy into vein, each additional hour | 82 | $20 | $161 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 81 | $20 | $128 |
| Irrigation of implanted venous access drug delivery device | 79 | $18 | $114 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 79 | $75 | $70 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 78 | $21 | $157 |
| Administration of additional new drug or substance into vein, 1 hour or less | 78 | $46 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 74 | $1 | $7 |
| Carcinoembryonic antigen (cea) protein level | 69 | $19 | $99 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 67 | $24 | $145 |
| Automated urinalysis | 66 | $2 | $16 |
| New patient office visit (45-59 min) | 55 | $109 | $565 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 44 | $122 | $500 |
| Infusion, normal saline solution , 1000 cc | 38 | $2 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 37 | $47 | $313 |
| PSA test (prostate cancer screening) | 35 | $18 | $94 |
| CT scan of chest, without contrast | 31 | $28 | $686 |
| Ct scan of chest with contrast | 31 | $35 | $821 |
| CT scan of abdomen and pelvis with contrast | 31 | $148 | $1,067 |
| Ct scan of abdomen and pelvis without contrast | 28 | $65 | $560 |
| Hospital follow-up visit, low complexity | 20 | $38 | $135 |
| Injection of drug or substance into vein | 17 | $28 | $247 |
| New patient office visit, complex (60-74 min) | 16 | $168 | $709 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 14 | $124 | $523 |
| Infusion into a vein for hydration, each additional hour | 14 | $10 | $75 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.8% high complexity
68.1% medium
31.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$71,149
Total received (2018-2024)
Avg $10,164/year across 7 years
Top 18% in TX for medical oncology
42
Companies
126
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$37,268 (52.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$31,726 (44.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,155 (3.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$198
2023$10,809
2022$7,629
2021$16,277
2020$2,169
2019$29,358
2018$4,709
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
TESARO, Inc.
$8,511
Merck Sharp & Dohme Corporation
$8,383
Novartis Pharmaceuticals Corporation
$6,609
Novocure Inc.
$5,584
AstraZeneca Pharmaceuticals LP
$4,963
Rigel Pharmaceuticals, Inc.
$4,386
Keryx Biopharmaceuticals, Inc.
$3,980
Karyopharm Therapeutics Inc.
$3,832
G1 Therapeutics, Inc.
$3,000
CTI BioPharma Corp.
$2,975
Fresenius Kabi USA, LLC
$2,620
Epizyme, Inc.,
$2,500
Lilly USA, LLC
$2,000
GlaxoSmithKline, LLC.
$1,950
AbbVie Inc.
$1,800
JAZZ PHARMACEUTICALS INC.
$1,518
Seagen Inc.
$1,225
TG THERAPEUTICS, INC.
$1,125
Daiichi Sankyo Inc.
$935
Bayer HealthCare Pharmaceuticals Inc.
$900
EMD Serono, Inc.
$519
GENZYME CORPORATION
$296
Janssen Biotech, Inc.
$229
Sirtex Medical Inc
$198
Genentech USA, Inc.
$174
Alexion Pharmaceuticals, Inc.
$150
Tactile Systems Technology Inc
$128
Amgen Inc.
$124
AVEO Pharmaceuticals, Inc.
$120
Edwards Lifesciences Corporation
$96
E.R. Squibb & Sons, L.L.C.
$56
Pharming Healthcare, Inc.
$52
Astellas Pharma US Inc
$30
PFIZER INC.
$28
PUMA BIOTECHNOLOGY, INC.
$27
Gilead Sciences, Inc.
$25
Ipsen Biopharmaceuticals, Inc
$22
Regeneron Healthcare Solutions, Inc.
$17
Adaptive Biotechnologies Corporation
$17
NESTLE HEALTHCARE NUTRITION INC.
$16
Stemline Therapeutics Inc.
$15
Takeda Pharmaceuticals U.S.A., Inc.
$12
Top 3 companies account for 33.0% of total payments
Associated products mentioned in payments ›
ADCETRIS · Alecensa · Auryxia · CALQUENCE · COSELA · CYRAMZA · DARZALEX · ELITEK · ELZONRIS · ENHERTU · ERLEADA · Edwards SAPIEN 3 Transcatheter Heart Valve · FOTIVDA · Flexitouch Plus · IMBRUVICA · IMLYGIC · JEMPERLI · KEYTRUDA · LIBTAYO · LUMAKRAS · LYNPARZA · NERLYNX · ONIVYDE · OPDIVO · Optune · Perjeta · Pomalyst · SARCLISA · SIR-Spheres Microspheres · Soliris · Stimufend · TAGRISSO · TASIGNA · TAZVERIK · TEPMETKO · Tavalisse · Tepmetko · Trodelvy · UKONIQ · VENCLEXTA · VOWST · VYXEOS · Vitrakvi · Vonjo · XPOVIO · XTANDI · Xtandi · ZEJULA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (52%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $269 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
0.5
County median income
$58,859
Nearest hospital
THE HOSPITALS OF PROVIDENCE - EAST CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Aloba is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (consulting-driven, top 18%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Aloba experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Aloba performed 9,600 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Aloba receive payments from pharmaceutical companies?
Yes. Dr. Aloba received a total of $71,149 from 42 companies across 126 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Aloba's costs compare to other medical oncologys in El Paso?
Dr. Aloba's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Aloba) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in El Paso
Browse medical oncologys in El Paso ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
TESARO, Inc. Payments to Doctors
See all physicians who received payments from TESARO, Inc..
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology